Canadian Originators Are Free To Try Again
Previous Failures In Asserting Patents Do Not Preclude Future Attempts
You may also be interested in...
With a biosimilar to Amgen’s Neupogen already on the market in the US, Pfizer has challenged key claims of Amgen’s Canadian drug substance patent, in an attempt to clear a path to market for its Nivestym biosimilar.
Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.